Overview

Use of 3,4-Diaminopyridine in the Treatment of Lambert-Eaton Syndrome

Status:
Approved for marketing
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To learn more about the effect of 3, 4-Diaminopyridine (3,4-DAP) on patient diagnosed with Lambert-Eaton myasthenic syndrome (LEMS).
Details
Lead Sponsor:
University of Colorado, Denver
Treatments:
3,4-diaminopyridine
4-Aminopyridine
Amifampridine